Free Trial

Jasper Therapeutics (JSPR) News Today

Jasper Therapeutics logo
$4.87 +0.05 (+1.04%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$4.89 +0.02 (+0.43%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

JSPR Latest News

Jasper Therapeutics, Inc. stock logo
Soleus Capital Management L.P. Has $31.95 Million Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Soleus Capital Management L.P. grew its position in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 11.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,494,420 shares of the company's stock after acquiring
Research Analysts Offer Predictions for JSPR Q2 Earnings
William Blair Has Negative Estimate for JSPR Q2 Earnings
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics (NASDAQ:JSPR) Releases Earnings Results, Misses Expectations By $0.24 EPS
Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) posted its earnings results on Monday. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.24).
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Acquired by Integral Health Asset Management LLC
Integral Health Asset Management LLC increased its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 85.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 650,000 shares of the company's stock after purchasing
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics (JSPR) Expected to Announce Earnings on Tuesday
Jasper Therapeutics (NASDAQ:JSPR) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-jasper-therapeutics-inc-stock/)
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Acquired by Braidwell LP
Braidwell LP increased its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 47.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 714,658 shares of the company's stock
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have earned an average recommendation of "Buy" from the nine brokerages that are currently covering the company, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy rating. The average 12-month price objectiv
Jasper Therapeutics, Inc. stock logo
Ally Bridge Group NY LLC Decreases Stock Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Ally Bridge Group NY LLC lessened its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 69.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 122,424 shares of the company's stock after selling 277,042 shares during the qu
Jasper Therapeutics, Inc. stock logo
Boxer Capital Management LLC Buys New Shares in Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Boxer Capital Management LLC bought a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 350,000 shares of the company's stock, valued at ap
Jasper Therapeutics, Inc. stock logo
T. Rowe Price Investment Management Inc. Makes New $1.76 Million Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)
T. Rowe Price Investment Management Inc. acquired a new stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 82,165 shares of the company'
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from Analysts
Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have earned an average rating of "Buy" from the nine brokerages that are presently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a buy rating. The average twelve-month price objective among analyst
Jasper Therapeutics, Inc. stock logo
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Decreases By 19.7%
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,670,000 shares, a decline of 19.7% from the February 28th total of 2,080,000 shares. Based on an average daily volume of 526,700 shares, the days-to-cover ratio is currently 3.2 days. Currently, 14.1% of the company's stock are short sold.
Jasper Therapeutics files $300M mixed securities shelf
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 2,080,000 shares, a decrease of 16.8% from the February 13th total of 2,500,000 shares. Currently, 17.5% of the company's shares are short sold. Based on an average trading volume of 522,500 shares, the days-to-cover ratio is currently 4.0 days.
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by Analysts
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has received a consensus rating of "Buy" from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy rating. The average twelve-month price target among brokera
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics (NASDAQ:JSPR) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday.
Jasper Therapeutics, Inc. stock logo
FY2025 EPS Estimates for JSPR Raised by Cantor Fitzgerald
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Jasper Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that
Jasper Therapeutics, Inc. stock logo
Equities Analysts Set Expectations for JSPR Q1 Earnings
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Investment analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research report issued on Thursday, February 27th. William Blair analyst M. Phipps anticipates that the compa
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics (NASDAQ:JSPR) Announces Earnings Results, Misses Estimates By $0.42 EPS
Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.42).
Jasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23)
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics (JSPR) to Release Quarterly Earnings on Monday
Jasper Therapeutics (NASDAQ:JSPR) will be releasing earnings before the market opens on Monday, March 3.
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from Brokerages
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eleven research firms that are presently covering the firm, Marketbeat.com reports. Eleven analysts have rated the stock with a buy rating. The average 12 month price target amo
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Down 15.5% in January
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 2,720,000 shares, a decline of 15.5% from the January 15th total of 3,220,000 shares. Approximately 24.2% of the shares of the company are sold short. Based on an average trading volume of 477,000 shares, the short-interest ratio is currently 5.7 days.
Jasper Therapeutics initiated with a Buy at UBS
Jasper Therapeutics, Inc. stock logo
UBS Group Begins Coverage on Jasper Therapeutics (NASDAQ:JSPR)
UBS Group initiated coverage on Jasper Therapeutics in a research note on Thursday. They set a "buy" rating and a $38.00 price objective on the stock.
Jasper Therapeutics, Inc. stock logo
Analysts Offer Predictions for JSPR FY2025 Earnings
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the
Jasper Therapeutics, Inc. stock logo
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 12.1%
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,320,000 shares, a growth of 12.1% from the December 15th total of 2,070,000 shares. Approximately 20.6% of the shares of the company are sold short. Based on an average daily trading volume, of 412,100 shares, the short-interest ratio is presently 5.6 days.
Jasper Therapeutics, Inc. stock logo
What is HC Wainwright's Forecast for JSPR Q1 Earnings?
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar forecasts that the company
Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital
Jasper Therapeutics, Inc. stock logo
HC Wainwright Has Lowered Expectations for Jasper Therapeutics (NASDAQ:JSPR) Stock Price
HC Wainwright dropped their target price on shares of Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday.
Jasper Therapeutics, Inc. stock logo
What is HC Wainwright's Forecast for JSPR FY2029 Earnings?
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar anticipates that the company wil
Jasper Therapeutics, Inc. stock logo
Jasper Therapeutics (NASDAQ:JSPR) Given New $48.00 Price Target at Royal Bank of Canada
Royal Bank of Canada decreased their target price on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research report on Thursday.
Jasper Therapeutics price target lowered to $64 from $90 at BTIG
Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.

JSPR Media Mentions By Week

JSPR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

JSPR
News Sentiment

-0.17

0.69

Average
Medical
News Sentiment

JSPR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

JSPR Articles
This Week

13

3

JSPR Articles
Average Week

Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:JSPR) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners